Cerus Corporation (CERS)
NASDAQ:CERS
Want to see CERS full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.01Last Year’s EPS
-0.03Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Q1 2026
Earnings Call Date:Apr 30, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented multiple clear commercial and operational positives: strong Q1 top-line performance (24% product revenue growth), raised full-year guidance, robust IFC/platelet momentum, continued positive adjusted EBITDA, disciplined operating expense control, and advancing regulatory/product milestones (illuminator PMA submission and RBC trial readout). Offsetting these positives are persistent margin headwinds (gross margin down to 52%), macro pressures (inflation, tariffs, FX), regional logistical risks (Middle East), working capital-driven cash use, and timing uncertainty around the red blood cell CE Mark and the lumpy nature of IFC rollout. On balance, the highlights—notably recurring revenue growth, improved profitability trends, and strengthened guidance—outweigh the lowlights, though management cautions about margin and timing risks.Company Guidance
Strong Product Revenue Growth and Raised Guidance
Q1 product revenue was $53.7M, up 24% year-over-year. Management raised full-year 2026 product revenue guidance to $227M–$231M (implying ~10%–12% YoY product revenue growth) and raised IFC guidance to $22M–$24M (~30%–40% growth for IFC).
Robust IFC / ISC Trajectory
First-quarter IFC/ISC momentum: IFC revenue was $5.7M vs $3.0M in Q1 2025 (~90% YoY revenue growth); therapeutic dose equivalents (ISC measure) increased ~120% YoY. Management cites early traction from BCA members and conversion from finished therapeutics to kit-based sales.
Platelet Franchise Strength and Market Penetration
North American platelet kit volumes (treatable doses) increased 69% YoY and North America comprised nearly 70% of Q1 product revenue. Early benefits from the Blood Centers of America (BCA) group purchasing agreement are noted, and international platelet demand (EMEA) also contributed to growth.
Broad Geographic Growth and FX Tailwind
Total revenue (including government contract revenue) rose 23% YoY. EMEA revenue grew 28% YoY, with EMEA FX contributing ~11% of that growth and consolidated FX contributing ~3% versus Q1 2025.
Improving Profitability Trends
GAAP net loss narrowed to $1.6M in Q1. Non-GAAP adjusted EBITDA was positive $4.0M, marking the eighth consecutive quarter of positive adjusted EBITDA, and company expects its third consecutive year of positive adjusted EBITDA in 2026 with line of sight to GAAP profitability.
Operating Discipline and R&D Efficiency
Operating expenses declined 7% YoY. SG&A was largely flat YoY. R&D spending declined as INT 200/INT 100 development winds toward regulatory submission and Cerus-funded R&D is trending down as a percent of total R&D (more spend shifted to government-reimbursed programs).
Cash Position and Long-Term Growth Track Record
Cash and equivalents of $80.4M (vs. $82.9M at 2025 year-end). Since 2019, product revenue CAGR is 18% and operating expenses have increased <3% annually, demonstrating operating leverage and sustained growth.
Regulatory & Product Milestones in Flight
Key near-term catalysts: PMA submission for illuminator device (INT 200/INT 100) planned this quarter with an anticipated U.S. launch in 2027; INTERCEPT red blood cell program completed RETA enrollment with expected readout Q4 2026 and ongoing ANSM review for CE Mark (management estimates potential H1 2027 timing).
CERS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CERS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $2.03 | ― | ― |
Mar 02, 2026 | $2.53 | $2.13 | -15.81% |
Nov 06, 2025 | $1.41 | $1.71 | +21.28% |
Aug 05, 2025 | $1.28 | $1.29 | +0.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cerus Corporation (CERS) report earnings?
Cerus Corporation (CERS) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Cerus Corporation (CERS) earnings time?
Cerus Corporation (CERS) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CERS EPS forecast?
CERS EPS forecast for the fiscal quarter 2026 (Q2) is -0.01.